Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Stop IPI-NIVO: Early Nivolumab Discontinuation in Melanoma
NCT05652673Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in melanoma, sponsored by Erasmus MC. Primary endpoint: Ongoing response at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05652673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652673.